Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients age 70 years and older with hormone receptor positive, HER2 negative breast cancer that has spread to other places in the body.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 70 lat
- •Spodziewana długość życia ponad 6 miesięcy
- •Potwierdzony rak piersi z receptorami hormonalnymi dodatnimi
- •Potwierdzony rак piersi HER2-ujemny
- •Rак piersi z przerzutami potwierdzonymi badaniem obrazowym
- •Progresja choroby pomimo wcześniejszego leczenia hormonalnego, palbocicklibem, ribocicklibem lub chemioterapią
- •Prawidłowa liczba białych krwinek (ANC ≥ 1,5 x 10⁹/L)
- •Prawidłowe wyniki badań nerek i wątroby
✗ Disqualifies
- •Poważna operacja chirurgiczna w ciągu 14 dni przed rozpoczęciem badania
Simplified criteria — AI translation
Trial details
- Minimum age
- 70 Years
- Last updated (source)
- May 4, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (6)
City of Hope Medical Center
Duarte, United States
City of Hope at Irvine Lennar
Irvine, United States
City of Hope at Long Beach Elm
Long Beach, United States
City of Hope South Pasadena
South Pasadena, United States
Dana Farber Cancer Institute
Boston, United States
Roswell Park Comprehensive Cancer Center
Buffalo, United States
Trial contact
Joanne Mortimer, MD
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.